BioNTech (BNTX) Stock Forecast & Price Target

Q: What analysts cover BioNTech?

BioNTech has been rated by research analysts at Argus , Berenberg Bank , BMO Capital Markets , Canaccord Genuity Group , Citigroup , Morgan Stanley , UBS Group , and Weiss Ratings in the past 90 days.

$87.71 -2.49 (-2.76%)

Closing price 04:00 PM Eastern

Extended Trading

$88.00 +0.29 (+0.32%)

As of 07:44 PM Eastern

Compare

BioNTech - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 20 Analyst Ratings

Sell
1

Hold
6

Buy
13

Based on 20 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 1 has given a sell rating, 6 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$125.44
43.01% Upside

According to the 20 analysts' twelve-month price targets for BioNTech, the average price target is $125.44. The highest price target for BNTX is $155.00, while the lowest price target for BNTX is $94.00. The average price target represents a forecasted upside of 43.01% from the current price of $87.71.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BNTX Analyst Ratings Over Time

Type	Current Forecast 10/16/25 to 10/16/26	1 Month Ago 9/16/25 to 9/16/26	3 Months Ago 7/18/25 to 7/18/26	1 Year Ago 10/16/24 to 10/16/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)	10 Buy rating(s)
Hold	6 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$125.44	$126.00	$129.13	$134.32
Forecasted Upside	43.01% Upside	31.48% Upside	41.15% Upside	27.82% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioNTech Stock vs. The Competition

Type	BioNTech	Healthcare Companies	Broader Market
Consensus Rating Score	2.65	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	42.18% Upside	1,202.74% Upside	17.72% Upside
News Sentiment Rating	Neutral News See Recent BNTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/14/2026	Canaccord Genuity Group 3 of 5 stars	John Newman 2 of 5 stars	Lower Target	Buy	$136.00 ➝ $132.00	+48.30%
10/8/2026	Argus 3 of 5 stars		Initiated Coverage	Hold
10/7/2026	Morgan Stanley 3 of 5 stars	Terence Flynn 5 of 5 stars	Lower Target	Overweight	$115.00 ➝ $114.00	+20.13%
10/2/2026	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Sell (D-)
9/16/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	David Dai Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy
9/16/2026	Berenberg Bank Subscribe to MarketBeat All Access to unlock brokerage rankings		Set Target		$140.00	+44.79%
9/8/2026	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Evan David Seigerman Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Outperform ➝ Market Perform	$128.00 ➝ $105.00	+1.20%
8/5/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Geoff Meacham Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$130.00 ➝ $125.00	+36.11%
6/5/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings	Jeffrey Walch Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Market Perform
6/1/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Akash Tewari Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy
Get the Latest News and Ratings for BNTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.
5/6/2026	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Mohit Bansal Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Overweight	$150.00 ➝ $140.00	+50.09%
4/27/2026	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Robert Burns Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy	$130.00	+23.27%
3/25/2026	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Asthika Goonewardene Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Strong-Buy
3/17/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Buy
3/11/2026	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Yaron Werber Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Hold	$116.00 ➝ $94.00	+4.49%
3/11/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Asad Haider Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy
3/10/2026	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Outperform
3/10/2026	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Buy	$128.00	+53.10%
2/2/2026	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings		Downgrade	Outperform ➝ Market Perform	$113.00	-0.66%
10/23/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Jessica Fye Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Neutral	$121.00 ➝ $120.00	+14.72%
11/19/2024	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Cory Kasimov Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	In-Line ➝ Outperform	$110.00 ➝ $125.00	+22.71%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 09:51 PM ET.

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, October 14, 2026. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

Here are some ways that investors could benefit from investing in BioNTech SE:

The stock is currently trading at $88.66, which is significantly below the consensus price target of $126.00 set by analysts, suggesting substantial potential upside for investors who believe in the company's long-term pipeline.
BioNTech SE maintains a strong balance sheet with a debt-to-equity ratio of 0.01 and a current ratio of 7.85, indicating the company has ample liquidity and minimal leverage to fund its ongoing research and development efforts without significant financial risk.
The company continues to advance its broad oncology pipeline, with multiple candidates such as BNT111, BNT112, and BNT114 in various phases of clinical trials for melanoma, prostate cancer, and triple-negative breast cancer, providing diversified opportunities beyond any single product.
Institutional interest remains strong, with major investors like Flossbach Von Storch SE and First Trust Advisors LP recently increasing their stakes, signaling confidence in the company's strategic direction and potential for future growth.
The AHEAD-MERIT trial for BNT113 will continue to gather overall-survival data, which analysts suggest could preserve a meaningful development and regulatory path for the drug, potentially limiting downside risk if longer-term results are favorable.

BioNTech
Bear Case

Investors should be bearish about investing in BioNTech SE for these reasons:

The BNT113 cancer vaccine recently missed its primary progression-free survival endpoint in the AHEAD-MERIT Phase 2/3 trial, a significant clinical setback that has deepened doubts about the company's broader mRNA cancer-vaccine strategy and led to a 7.1% drop in the stock price.
BioNTech SE is currently unprofitable, with a negative P/E ratio of -11.32 and a negative net margin of 63.54% in the most recent quarter, indicating that the company is spending significantly more than it is earning from its operations.
Revenue has declined sharply, with the most recent quarter showing a 59.5% year-over-year decrease to $122.31 million, well below the consensus estimate of $180.18 million, reflecting a challenging commercial environment for the company's products.
CEO Ugur Sahin has been actively selling shares, recently selling 36,209 shares at an average price of $95.37, which represents a 50% decrease in his direct position and may signal a lack of confidence in the near-term stock performance.
Analyst sentiment has turned more cautious, with several firms like BMO Capital Markets and Canaccord Genuity Group lowering their price targets and ratings, reflecting concerns about the company's ability to execute on its clinical and commercial goals.

BNTX Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $125.44, with a high forecast of $155.00 and a low forecast of $94.00.

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There is currently 1 sell rating, 6 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BNTX shares.

According to analysts, BioNTech's stock has a predicted upside of 43.01% based on their 12-month stock forecasts.

Over the previous 90 days, BioNTech's stock had 1 downgrade by analysts.

BioNTech has been rated by research analysts at Argus, Berenberg Bank, BMO Capital Markets, Canaccord Genuity Group, Citigroup, Morgan Stanley, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like BioNTech more than other "healthcare" companies. The consensus rating for BioNTech is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how BNTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With BioNTech Recommendations

MarketBeat monitors more than a dozen sources for BioNTech analyst ratings, with the most recent rating issued on 10/14/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioNTech (BNTX) Stock Forecast & Price Target